MedTrace Logo

Relationship Between Breast Cancer Subtypes and Immune Checkpoints

NCT05460702 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2023-02-16

No results posted yet for this study

Summary

Breast cancer is the most common type of cancer in women and the second most common cause of death after lung cancer. The luminal group A, which has the highest prevalence among breast cancers; It includes Her2-negative tumors with low proliferative activity, low mitotic rate and histological grade. The prognosis of patients with luminal A tumors is very good and metastases are mostly limited to bones. Luminal-B tumors have a more aggressive course. The most important difference of this group is that tumors have a high proliferation rate. The breakpoint between luminal A and B is generally accepted as less than 14% of tumor cells showing nuclear Ki67 expression immunohistochemically. In addition, approximately 30% of Her2-positive tumors are immunohistochemically in the luminal B phenotype.

Up or down regulation of immune checkpoints is observed to protect breast cancer cells from the anti-tumor responses of the immune system. There are few studies in the literature evaluating soluble immune checkpoints in breast cancer, and these studies did not evaluate soluble immune checkpoints according to the histopathological subtyping of breast cancer.

The aim of this study is to determine the relationship between Luminal A, Luminal B and triple negative breast cancer and soluble immune control points, and to guide possible potential immunotherapy treatments.

Conditions

Interventions

DIAGNOSTIC_TEST

Soluble immune checkpoints

Blood collection from breast cancer patients with stage I-II

Sponsors & Collaborators

  • Istanbul Training and Research Hospital

    lead OTHER_GOV

Principal Investigators

  • Ufuk Oguz Idiz, Assoc.Prof. · Istanbul Training and Research Hospital

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2022-12-01
Completion
2022-12-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05460702 on ClinicalTrials.gov